Management of Antiplatelet Therapy and Carboplatin Dosing in Patients with Severe Renal Impairment

Antiplatelet Therapy in Severe Renal Dysfunction

Aspirin does not require dose adjustment in renal impairment, but formal assessment and documentation of bleeding risk should be performed for every patient with renal dysfunction. 1
Dual antiplatelet therapy (aspirin + clopidogrel) may be continued in carefully selected patients undergoing chemotherapy, provided there is no active bleeding or severe thrombocytopenia. (Guideline recommendation) 1

Carboplatin is preferred over cisplatin in patients with renal impairment (GFR < 60 mL/min) because it is less nephrotoxic; however, response rates are lower (≈ 26 % vs 42 % in patients with preserved renal function). 2
Carboplatin dosing must be calculated with the Calvert formula (Dose = target AUC × [GFR + 25]) to incorporate the patient’s measured or estimated GFR and avoid overdosing. (Guideline recommendation)

A formal bleeding risk score should be calculated and recorded before every carboplatin cycle; severe renal impairment (GFR < 15 mL/min) is itself a high‑risk criterion. 3
Modifiable bleeding risk factors—such as active peptic ulcer disease, recent bleeding events, concurrent anticoagulation, thrombocytopenia, or other coagulopathies—must be identified and addressed. 1
Baseline complete blood count, platelet count, and coagulation parameters should be obtained to establish reference values for subsequent monitoring. 1

Aggressive hydration (modified for renal impairment) should be maintained during carboplatin administration; although carboplatin requires less hydration than cisplatin, adequate fluid support helps prevent further renal decline. 2

Antiplatelet therapy should not be discontinued solely because of renal impairment or chemotherapy; the cardiovascular/cerebrovascular risk of stopping secondary‑prevention agents generally outweighs the bleeding risk. [1][6]
Cisplatin is contraindicated in patients with GFR ≈ 15 mL/min; carboplatin is the appropriate platinum agent. 2

Hold aspirin and/or clopidogrel only if any of the following occur: platelet count < 50 × 10⁹/L, active bleeding, or an urgent invasive procedure with high bleeding risk. [1][3]
If clopidogrel must be stopped for a procedure, discontinue it 5–7 days beforehand (longer in severe renal impairment) and resume 24–48 hours after confirmed hemostasis. 1
Aspirin may be held 3–5 days before high‑bleeding‑risk procedures and restarted within 24 hours post‑procedure if hemostasis is adequate. 1